In the original article, Boulland et al. (94) and Carbonelle-Puscian et al. (95) were not cited in the article. These references have now been inserted in Mechanisms of Tumor Microenvironment Mediated Immune Evasion and Tumor Progression in NHL, Paragraph Number 2:
Inhibitory enzymes, like indolediamine oxidase (IDO), and phenylalanine oxidase interleukin 4-induced gene 1 (IL4I1), secreted by lymphoma associated macrophages and some B-NHL cells also contributes to immune suppression by Treg expansion and inhibition of effector T cell proliferation and activity (94, 95).
The citations for Boulland et al. (94) and Carbonelle-Puscian et al. (95) have also been inserted in the legend for Figure 1:
IDO and IL4I1 are also responsible for recruitment and differentiation of immunosuppressive Tregs, as well as exhaustion of T-effector cells through CCL22, TGF-β, and IL-12 secretion. FAS Ligand (FASL) induces apoptosis of CTLs (94, 95).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
94.
BoullandMMarquetJMolinier-FrenkelVMollerPGuiterCLasoudrisFet al. Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits, T-lymphocyte proliferation. Blood (2007). 110:220–7. 10.1182/blood-2006-07-036210
95.
Carbonelle-PuscianACopie-BergmanCMartin-GarciaNAlloryYHaiounCCremandesAet al. The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages. Leukemia (2009). 23:952–60. 10.1038/leu.2008.380
Summary
Keywords
lymphoma, microenvironment, T cell subsets, stromal cells, lymphoma exosomes
Citation
Kumar D and Xu ML (2018) Corrigendum: Microenvironment Cell Contribution to Lymphoma Immunity. Front. Oncol. 8:522. doi: 10.3389/fonc.2018.00522
Received
05 October 2018
Accepted
24 October 2018
Published
08 November 2018
Volume
8 - 2018
Edited and reviewed by
Alexandar Tzankov, Universitätsspital Basel, Switzerland
Updates
Copyright
© 2018 Kumar and Xu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mina L. Xu Mina.xu@yale.edu
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.